Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | RA Capital Management, L.P. | 4,397,368 9.600% | 40,736 (+0.94%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | RA Capital Management, L.P. | 3,773,517 19.500% | 106,854 (+2.91%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | BELLUS Health Inc. BLU | RA Capital Management, L.P. | 12,452,574 9.900% | 2,222,300 (+21.72%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | RA Capital Management, L.P. | 5,999,481 8.600% | 2,387,274 (+66.09%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,408,706 9.990% | 1,801,847 (+112.13%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Vaxcyte, Inc. PCVX | RA Capital Management, L.P. | 8,153,559 9.990% | 4,287,751 (+110.91%) | Filing History |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 3,853,867 8.900% | 668,036 (+20.97%) | Filing History |
| 2023-01-10 5:11 pm Purchase | 2023-01-06 | 13D | 89bio, Inc. ETNB | RA Capital Management, L.P. | 6,159,054 17.960% | 1,854,607 (+43.09%) | Filing History |
| 2023-01-06 4:30 pm Purchase | 2023-01-04 | 13G | Fulcrum Therapeutics, Inc. FULC | RA Capital Management, L.P. | 9,686,628 18.600% | 2,686,628 (+38.38%) | Filing History |
| 2022-12-30 4:57 pm Sale | 2022-12-28 | 13D | Achilles Therapeutics plc ACHL | RA Capital Management, L.P. | 1,607,834 13.000% | -1,369,109 (-45.99%) | Filing History |
| 2022-12-30 4:30 pm Purchase | 2022-12-20 | 13G | Avidity Biosciences, Inc. RNA | RA Capital Management, L.P. | 5,454,533 8.210% | 5,454,533 (New Position) | Filing History |
| 2022-12-23 5:15 pm Sale | 2022-12-21 | 13D | Achilles Therapeutics plc ACHL | RA Capital Management, L.P. | 2,976,943 13.000% | -1,130,565 (-27.52%) | Filing History |
| 2022-12-15 5:01 pm Sale | 2022-12-13 | 13D | Achilles Therapeutics plc ACHL | RA Capital Management, L.P. | 4,107,508 13.000% | -907,179 (-18.09%) | Filing History |
| 2022-12-09 4:31 pm Purchase | 2022-12-07 | 13D | Vor Biopharma Inc. VOR | RA Capital Management, L.P. | 1,138,007 34.800% | 581,442 (+104.47%) | Filing History |
| 2022-12-05 5:12 pm Purchase | 2022-12-02 | 13D | Solid Biosciences Inc. SLDB | RA Capital Management, L.P. | 3,431,618 17.570% | 2,601,760 (+313.52%) | Filing History |
| 2022-12-02 4:30 pm Purchase | 2022-11-22 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA Capital Management, L.P. | 4,333,333 5.290% | 4,333,333 (New Position) | Filing History |
| 2022-11-28 4:31 pm Purchase | 2022-11-17 | 13D | Acrivon Therapeutics, Inc. Common Stock ACRV | RA Capital Management, L.P. | 4,813,442 23.070% | 4,813,442 (New Position) | Filing History |
| 2022-11-14 4:46 pm Purchase | 2022-11-10 | 13D | Vor Biopharma Inc. VOR | RA Capital Management, L.P. | 556,565 28.780% | 516 (+0.09%) | Filing History |
| 2022-11-14 4:43 pm Unchanged | 2022-11-14 | 13G | Standard BioTools Inc. LAB | RA Capital Management, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-11-14 4:43 pm Sale | 2022-11-14 | 13G | LianBio LIANY | RA Capital Management, L.P. | 0 0.000% | -7,655,015 (Position Closed) | Filing History |